Skip to main content
. 2022 Apr 30;34(2):71–82. doi: 10.21147/j.issn.1000-9604.2022.02.02

Table 1. Characteristics of study cohorts.

Variables n (%) P
Training
cohort
(N=624)
Validation
cohort
(N=307)
KPS, Karnofsky performance status; LN, lymph node; cTNM, clinical TNM stage; pTNM, pathological TNM stage.
Age (year) 0.062
 <65 457 (73.2) 206 (67.1)
 ≥65 167 (26.8) 101 (32.9)
Gender 0.894
 Male 526 (84.3) 257 (83.7)
 Female 98 (15.7) 50 (16.3)
KPS 0.308
 90−100 367 (58.8) 192 (62.5)
 70−80 257 (41.2) 115 (37.5)
Tumor location 0.872
 Upper 181 (29.0) 84 (27.4)
 Middle 310 (49.7) 156 (50.8)
 Lower 133 (21.3) 67 (21.8)
Differentiation 0.871
 G1 119 (19.1) 63 (20.5)
 G2 238 (38.1) 115 (37.5)
 G3 267 (42.8) 129 (42.0)
Surgical margin 0.056
 R0 586 (93.9) 298 (97.1)
 R1/2 38 (6.1) 9 (2.9)
Vascular invasion 0.779
 No 508 (81.4) 253 (82.4)
 Yes 116 (18.6) 54 (17.6)
Neural invasion 0.015
 No 517 (82.9) 233 (75.9)
 Yes 107 (17.1) 74 (24.1)
Resected LN number 0.544
 <20 276 (44.2) 143 (46.6)
 ≥20 348 (55.8) 164 (53.4)
cTNM 0.089
 I 9 (1.4) 5 (1.6)
 II 167 (26.8) 69 (22.5)
 III 238 (38.1) 104 (33.9)
 IV 210 (33.7) 129 (42.0)
pTNM (8th) 0.588
 I 43 (6.9) 23 (7.5)
 II 202 (32.4) 93 (30.3)
 III 289 (46.3) 151 (49.2)
 IV 90 (14.4) 40 (13.0)